Gaxenim 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

gaxenim 0,5 mg kapsel, hård

bausch health ireland ltd - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Fingolimod Krka 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

fingolimod krka 0,5 mg kapsel, hård

krka d.d., novo mesto - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans

Fingolimod Tillomed 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

fingolimod tillomed 0,5 mg kapsel, hård

tillomed pharma gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne

Inzolfi 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

inzolfi 0,5 mg kapsel, hård

sandoz a/s - fingolimodhydroklorid - kapsel, hård - 0,5 mg - propylenglykol hjälpämne; mannitol hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans

Vumerity الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

vumerity

biogen netherlands b.v. - diroximel fumarate (biib098) - multipel skleros, skovvis förlöpande - immunsuppressiva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Fingolimod Mylan الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydroklorid - multipel skleros, skovvis förlöpande - immunsuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 och 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Golpimec 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

golpimec 0,5 mg kapsel, hård

neuraxpharm sweden ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - propylenglykol hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans

Fingolimod Bluefish 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

fingolimod bluefish 0,5 mg kapsel, hård

bluefish pharmaceuticals ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - propylenglykol hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans

Fingolimod Reddy 0,5 mg Kapsel, hård السويد - السويدية - Läkemedelsverket (Medical Products Agency)

fingolimod reddy 0,5 mg kapsel, hård

reddy holding gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - natriumlaurilsulfat hjälpämne; betadex hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans